| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
The undifferentiated type of post-H. pylori eradication gastric cancer, which is considered to have poor prognosis, is characterized by a high ratio of females, a deep depth invasion, and no follow-up. Therefore, careful screening requires attention. Genetic analysis with next generation sequencing of 20 gastric cancers revealed that the oncogene mutation, TP53, PIK3CA, ATM, MET, IDH1, and ERBB4 , were involved in post-eradication gastric cancer tissues, compared with non-cancerous tissue, such as H. pylori uninfected, and chronic gastritis. 17 years follow-up after eradication, histological atrophy improved, but intestinal metaplasia did not. Male gender had a higher degree of intestinal metaplasia than female. After eradication, males, advanced atrophy and intestinal metaplasia, and the appearance of oncogene mutations such as TP53, ATM, and MET are considered to be high-risk groups for gastric cancer after eradication, and careful follow-up should be focused on these factors.
|
